Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 10/20 | 0.64 |
| ▸ | MGLL | Q99685 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 7/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.59 |
| ▸ | LPL | P06858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LIPC | P11150 | 1/20 | 0.59 |
| ▸ | PNLIP | P16233 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | FASN | P49327 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.59 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.59 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.59 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL27962464 | 1.00 | DAGLA (0.64) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL9267899 | 1.00 | DAGLA (0.64) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL28745648 | 0.99 | DAGLA (0.63) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL28240792 | 0.99 | DAGLA (0.63) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL28360069 | 0.99 | DAGLA (0.63) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL28888021 | 0.99 | DAGLA (0.63) | DAGLAMGLLCNR1CNR2DAGLB | |
| Water SCHEMBL28163550 | 0.99 | DAGLA (0.63) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL27806391 | 0.99 | DAGLA (0.63) | DAGLAMGLLCNR1CNR2DAGLB | |
| Methyl Alcohol SCHEMBL27962463 | 0.97 | DAGLA (0.65) | DAGLAMGLLCNR1CNR2DAGLB | |
| SCHEMBL9269609 | 0.91 | DAGLA (0.54) | DAGLAMGLLCNR1CNR2DAGLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-104736147-A | Compositions and methods for weight management | UNIGEN INC | 2015-06-24 | — | — | CN | claimed |
| JP-4737836-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| JP-2003500451-A | — | — | 2003-01-07 | — | — | JP | claimed |
| CN-1365284-A | Dietary or pharmaceutical composition for preventing or treating hyperoxaluria | VSL PHARMACEUTICAL CO LTD (IE) | 2002-08-21 | — | — | CN | claimed |
| EP-1181027-A2 | DIETARY OR PHARMACEUTICAL COMPOSITION FOR USE FOR THE PREVENTION OR TREATMENT OF HYPEROXALURIA | VSL Pharma Limited (IE) | 2002-02-27 | — | — | EP | claimed |
| WO-2000072855-A2 | DIETARY OR PHARMACEUTICAL COMPOSITION FOR USE FOR THE PREVENTION OR TREATMENT OF HYPEROXALURIA | VSL PHARMA LIMITED (IE) | 2000-12-07 | — | — | WO | claimed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20240342096-A1 | MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS | EMPROS PHARMA AB (SE) | 2024-10-17 | — | — | US | disclosed |
| EP-4364743-A3 | A MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS | Empros Pharma AB (SE) | 2024-08-28 | — | — | EP | disclosed |
| US-12048694-B2 | Coordinated metabolic reprogramming in response to productive viral infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240226024-A1 | SYNERGISTIC EFFECTS ON WEIGHT LOSS, IMPROVED QUALITY OF LIFE AND REDUCED GASTRO-INTESTINAL SIDE EFFECTS WITH A COMPOSITION OF ORLISTAT AND ACARBOSE | EMPROS PHARMA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| EP-4086343-A4 | USE OF BIOLOGICAL ENZYME FOR PREPARING ORLISTAT INTERMEDIATE, AND PREPARATION METHOD | ZEIN BIOTECHNOLOGY CO., LTD. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2000072855-A2 | DIETARY OR PHARMACEUTICAL COMPOSITION FOR USE FOR THE PREVENTION OR TREATMENT OF HYPEROXALURIA | VSL PHARMA LIMITED (IE) | 2000-12-07 | — | — | WO | disclosed |
| EP-1039900-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999033450-A3 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | KNOLL AG (DE) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999033450-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5466708-A | Carbamyloxyoxetanone compounds | HOFFMANN-LA ROCHE INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5376674-A | Lipase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5260310-A | Oxetanone compounds and pharmaceutical compositions containing them | HOFFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048694-B2 | Coordinated metabolic reprogramming in response to productive viral infections | MAVS, ATF4, PC | DAGLA 4165/4885MGLL 1552/4885CNR1 3791/4885 |
| US-20240226024-A1 | SYNERGISTIC EFFECTS ON WEIGHT LOSS, IMPROVED QUALITY OF LIFE AND REDUCED GASTRO-INTESTINAL SIDE EFFECTS WITH A COMPOSITION OF ORLISTAT AND ACARBOSE | FABP6, SI, FABP2 | DAGLA 111/4885MGLL 7/4885CNR1 1466/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DAGLA 4201/4885MGLL 2940/4885CNR1 3597/4885 |
| US-20240342096-A1 | MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS | LIPC, ACAT2, ACACB | DAGLA 83/4885MGLL 11/4885CNR1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.